Spravato for Depression
If traditional antidepressants have failed to provide relief or side effects are intolerable, or if you face an acute depressive crisis, you need immediate intervention. Spravato (esketamine) offers a breakthrough alternative to daily SSRI/SNRI regimens. By targeting NMDA receptors rather than serotonin, Spravato can initiate symptom relief within hours. Patients in South Florida can access this rapid-acting, clinically supervised therapy at Ketamine Wellness Clinic in Pompano Beach.
22.5%
Of patients using Spravato for depression achieved remission by week 4, compared to just 7.6% with placebo [JAMA Psychiatry 2018]
24 hours
Symptom improvement can begin as early as 24 hours after the first dose. [FDA.gov 2019]
56 mg / 84 mg
Twice weekly is the standard induction schedule for adults under 65 (starting at 56 mg on Day 1, with subsequent doses at 56 mg or 84 mg).
Authorized
Since March 2019 for treatment-resistant depression and MDD with suicidal ideation in adults
What Is Spravato Used For?
Spravato (esketamine) nasal spray is indicated specifically for two clinical presentations in adult patients:
1. Treatment-Resistant Depression (TRD)
Clinicians diagnose TRD when an individual completes at least two separate antidepressant courses at adequate doses and durations without experiencing sufficient symptom reduction. Treatment resistance reflects how individual neurochemistry interacts with standard drugs, rather than a lack of patient effort.
Findings from the landmark STAR*D trial, the psychiatric field’s largest clinical study on depression, reveals that the likelihood of achieving remission falls sharply after two unsuccessful medication trials. Spravato provides an advanced, mechanism-driven alternative for individuals reaching this critical threshold. [NIMH 2006]
2. Major Depressive Disorder (MDD) with Acute Suicidal Ideation or Behavior
This treatment is also authorized for adults diagnosed with MDD who face acute suicidal thoughts or behaviors. Because standard oral antidepressants typically take several weeks to exert therapeutic effects, acute crisis scenarios demand faster intervention.
In clinical trials, many patients in crisis saw their symptoms ease within the first 24 hours. Results vary from person to person, and Spravato is always used alongside other psychiatric care, not on its own. Individuals seeking care under this indication do not need a prior history of antidepressant failures to qualify.
How Depression Shows Up in TRD and Suicidal Crisis
Depressive disorders present differently across individual patient profiles. While some patients endure chronic, treatment-resistant symptoms that persist across multiple pharmaceutical regimens, others face acute psychiatric emergencies requiring immediate medical oversight.
Symptom domain
Persistent Low Mood
Loss of Interest (Anhedonia)
Profound Fatigue
Cognitive Impairment
Disrupted Sleep Patterns
Emotional Blunting
Pervasive Hopelessness
Suicidal Thoughts
Practical & Clinical Manifestation
Experiencing a continuous sense of emptiness or emotional weight that persists despite adherence to daily antidepressant medications.
Losing all drive or satisfaction from hobbies, career milestones, and personal relationships that previously brought joy.
Waking up drained and remaining physically exhausted throughout the day, rendering routine tasks exhausting.
Experiencing persistent “brain fog,” marked by difficulty concentrating, retaining information, or processing simple tasks.
Struggling with severe insomnia, restless sleep cycles, or hypersomnia (sleeping 12+ hours while waking unrefreshed).
Feeling unable to express or experience natural emotional ranges, including grief, anger, excitement, or affection.
Carrying a persistent belief that clinical recovery is impossible and that standard therapies will continue to fail.
Experiencing frequent ideation regarding death, active suicidal planning, or self-harm urges, a state requiring immediate clinical intervention.
Regulatory Context
Spravato (esketamine) nasal spray was first authorized in March 2019 for use in conjunction with an oral antidepressant for the treatment of treatment-resistant depression in adults. In 2020, the indication was expanded to include depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior.
Age eligibility: Spravato is authorized for use in adults aged 18 and older. It is not indicated for children or adolescents.
Spravato is a Schedule III controlled substance and is only available through a restricted REMS (Risk Evaluation and Mitigation Strategy) program. It cannot be taken at home. Every dose must be administered in a certified healthcare setting under direct supervision.
Who it’s for:
Indication
Treatment-Resistant Depression (TRD)
MDD with Acute Suicidal Ideation or Behavior
Patient Profile
Adults who have not responded adequately to at least two prior antidepressant treatments in the current episode
Adults with major depressive disorder who are experiencing suicidal thoughts or actions,regardless of how many antidepressants they’ve tried
How Spravato Works
Conventional antidepressants (SSRIs and SNRIs) focus primarily on modulating serotonin and norepinephrine levels, a process that requires weeks to alter neural signaling and fails to benefit a significant portion of patients.
Spravato operates through an entirely distinct biological mechanism by targeting N-methyl-D-aspartate (NMDA) receptors within the brain’s glutamatergic system. Esketamine works as an NMDA receptor antagonist, acting on the brain’s glutamate system rather than serotonin. Researchers believe this helps support the brain’s ability to form new connections between nerve cells, which may be part of why it can ease symptoms faster than a standard antidepressant. Scientists are still studying exactly how it works.
Analogy: Conventional antidepressants function like detours around a traffic jam, slowly rerouting neural signals over several weeks. Spravato acts directly on the obstruction itself, clearing neural pathways to restore communication within hours.
Rapid Intervention for Acute Suicidal Crisis
When someone is in crisis with suicidal thoughts, waiting 2–6 weeks for an antidepressant to work isn’t an option. Spravato offers a rapid-acting intervention when urgent stabilization is paramount. Data from pivotal clinical trials confirm that patients presenting with major depressive disorder (MDD) and acute suicidal ideation who received Spravato demonstrated:
Significant improvement in depressive symptoms and measurable reductions in overall severity within 24 hours of the first dose.
Accelerated and rapid reduction in suicidal ideation compared to control groups receiving placebo.
Sustained therapeutic relief maintained across a 4-week treatment block.
This doesn’t mean Spravato is a standalone cure; medical guidelines require pairing it with an oral antidepressant and comprehensive psychiatric care. But for someone in crisis, those first 24 hours can make all the difference.
What to Expect During Your Spravato Care Protocol
Completing a successful treatment course requires structured clinical scheduling. Here is how our medical team structures your care path:
01
Diagnostic Evaluation
Our psychiatric prescribers evaluate your medical history, confirm diagnostic eligibility, and verify that Spravato aligns with your clinical needs.
02
Integrated Treatment Planning
We coordinate directly with your existing healthcare providers to integrate Spravato alongside an appropriate oral antidepressant regimen.
03
In-Clinic Self-Administration
During the 4-week induction phase, patients attend twice-weekly clinical sessions. Under direct staff observation, you self-administer the nasal spray (starting at 56 mg on Day 1, with subsequent doses of 56 mg or 84 mg) in a private suite.
04
Two-Hour Safety Monitoring
Clinical staff monitor your blood pressure, vital signs, and overall alertness for at least two hours post-administration to ensure patient safety before discharge. Patients often feel temporary dissociative sensations during this window.
05
Maintenance & Tapering
After the initial 4 weeks, dosing frequency tapers to once weekly for Weeks 5 through 8, transitioning to biweekly sessions or further tapering based on your long-term clinical response.
Comparing Advanced Depression Treatment Modalities
Feature
Mechanism
Onset of Action
Administration
Anesthesia
Driving Afterward
Primary Target
(Esketamine)
NMDA receptor antagonist
Hours (as early as 24h)
Nasal Spray (In-clinic)
No
No (Driver required)
TRD & Acute Suicidal Crisis
Oral Antidepressants
SSRI/SNRI (Monoamines)
Weeks
Daily Oral (At home)
No
Yes
Mild to Moderate Depression
TMS Therapy
Electromagnetic pulses
Weeks
Daily sessions
No
Yes
Treatment-Resistant Depression (TRD)
ECT
Induced seizure
Days/Weeks
Clinical setting
Yes
No
Severe Refractory Disorders
Why Choose Spravato for Depression Over Other Options
Over SSRIs/SNRIs: If you’ve tried standard antidepressants and they haven’t worked, or the side effects were intolerable, Spravato for depression offers a completely different mechanism. It doesn’t rely on serotonin. It works on glutamate. And it works fast.
Over ECT: ECT is effective but requires anesthesia and carries risks of memory loss. Spravato offers a less invasive option with a different side-effect profile, though both have their place in treatment.
Over TMS: TMS is another non-medication option for TRD. But TMS requires daily sessions for weeks and takes longer to show effect. Spravato can show improvement within hours. Some patients benefit from both approaches at different points in their recovery.
For suicidal crisis: If you’re experiencing suicidal thoughts, waiting weeks for an antidepressant to work isn’t safe. Spravato offers rapid relief within 24 hours, when you need it most.
Over doing nothing: Depression, whether treatment-resistant or in crisis, is not a life sentence. It’s a condition that requires a different approach. Spravato can be that approach for the right patient.
Clinical Evidence
Spravato’s efficacy is supported by multiple Phase 3 clinical trials, including TRANSFORM-2, SUSTAIN-1, and ASPIRE I/II.
For Treatment-Resistant Depression (TRD):
In a randomized, double-blind, placebo-controlled study, 22.5% of patients using Spravato for depression achieved remission by week 4, compared to 7.6% in the placebo group.
Improvement in MADRS total score was observed as early as 24 hours after the first dose and sustained through at least 4 weeks of treatment.
Real-world data from a Phase IV study of 570 patients showed significant MADRS score improvements of 14.4 points at 12 weeks and 17.6 points at 48 weeks of treatment.
Long-term studies show reduced relapse risk with continued maintenance treatment. [The Lancet 2019]
For MDD with Suicidal Ideation:
In the ASPIRE I and II trials, patients receiving Spravato showed significant improvement in depressive symptoms within 24 hours [American Journal of Psychiatry 2021]
Suicidal ideation scores improved more rapidly compared to placebo
Benefits were sustained over 4 weeks of treatment
Safety: Spravato is generally well-tolerated in clinical and real-world settings. The most common side effects include dissociation, dizziness, nausea, sedation, increased blood pressure, and a feeling of being ‘drunk’. These effects typically resolve the same day.
Frequently Asked Questions About Depression Treatment
What is Spravato?
Spravato is a prescription esketamine nasal spray authorized for adults with treatment-resistant depression or major depressive disorder with acute suicidal ideation or behavior. Spravato for depression works differently from standard antidepressants by targeting the brain’s glutamate system.
How is Spravato different from ketamine?
Spravato contains esketamine, which is one component of ketamine. It is authorized, has a standardized dosing protocol, and is administered in a controlled medical setting.
How fast does Spravato work?
Studies show symptom improvement can begin within hours to 24 hours after the first dose. This is significantly faster than standard antidepressants, which typically take 2-6 weeks.
Can Spravato be used for suicidal thoughts?
Yes. Spravato is authorized for adults with major depressive disorder who are experiencing acute suicidal ideation or behavior. It can begin reducing symptoms within 24 hours.
Do I need to have tried other antidepressants first?
For treatment-resistant depression, yes; you need to have tried at least two antidepressants without adequate relief. For MDD with suicidal ideation, no, you may qualify even if you haven’t tried multiple antidepressants.
Does Spravato hurt?
Clinical data shows that advanced glutamatergic options like Spravato and IV ketamine can initiate significant symptom improvement and a reduction in suicidal thoughts within hours to 24 hours after your very first dose.
What does Spravato feel like?
Many people describe a dissociative or dreamlike experience during the session. This typically resolves within 1-2 hours. You may feel drowsy, dizzy, or ‘out of it’ temporarily.
Why do I need to stay for 2 hours after?
Spravato can cause sedation, dissociation, and blood pressure changes. The 2-hour monitoring period ensures your safety and that you’re stable before you leave.
Can I drive myself home?
No. You should arrange for a driver to pick you up after each session. You cannot drive or operate heavy machinery for the rest of the day after treatment.
How long does treatment last?
The induction phase is 4 weeks of twice-weekly dosing (8 sessions total). Maintenance dosing then continues weekly or biweekly based on your response. The total number of sessions varies per patient.
Is Spravato covered by insurance?
Many plans cover Spravato for treatment-resistant depression and MDD with suicidal ideation. We accept most major carriers including Aetna, BCBS, Cigna, UnitedHealthcare, and Medicare. Our team verifies your benefits and handles prior authorizations.
What if Spravato doesn't work for me?
Not every treatment works for every person. Your psychiatric provider will monitor your progress and adjust your treatment plan if needed, including other options like TMS therapy or medication adjustments.
Find Out More
Contact us today and learn how Ketamine Clinic can guide your personal wellness journey.
By Appointment Only
Pompano Beach
41 N Federal Hwy, Suite A, 2nd Floor Pompano Beach, FL 33062
(954) 320-4944
(954) 400-5805
contact@ketamineclinicsouthflorida.com